# A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

> **NCT07253285** · PHASE3 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 460 (estimated)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** Cagrilintide
- **DRUG:** Semaglutide
- **DRUG:** Placebo cagrilintide
- **DRUG:** Placebo semaglutide

## Key facts

- **NCT ID:** NCT07253285
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-08
- **Primary completion:** 2030-03-20
- **Final completion:** 2033-09-20
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07253285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07253285, "A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07253285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*